NCT04828005View on ClinicalTrials.gov

Pharmacodynamic Evaluation of Intranasal Nalmefene

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

March 14, 2022

Study Completion Date

March 14, 2022

Conditions
Pharmacodynamic
Interventions
DRUG

Nalmefene hydrochloride

3mg Nasal spray

DRUG

Naloxone hydrochloride

4mg Nasal Spray

Trial Locations (1)

84124

PRA Health Sciences, Salt Lake City

Sponsors
All Listed Sponsors
lead

Opiant Pharmaceuticals Inc

INDUSTRY